ACE and type 2 diabetes mellitus: For instance, in addition to newer glucose-lowering agents for glycemic control, the use of other pharmacological agents (e.g., statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker) to prevent vascular complications is currently a crucial treatment strategy for type 2 diabetes populations; these agents were less emphasized when the UKPDS trial was conducted.